Evidence Partners AI-Based SLR Platform Attracts $20 Million in Growth Financing
Evidence Partners, developer of AI-enabled literature review automation software and creator of DistillerSR, has closed a $20 million growth financing round led by Thomvest Ventures with participation from Pender Ventures and Export Development Canada (EDC). The funds will be used to accelerate global growth and hire additional product, engineering, sales, marketing and customer success talent.
Bootstrapped since its formation in 2008, Evidence Partners has been a pioneer in the development of AI-enabled literature review software through its DistillerSR platform, which has experienced double-digit growth since its launch in 2009. Today, more than 300 research organizations are using DistillerSR to produce transparent, audit-ready and regulatory compliant literature reviews.
“This new funding will allow us to further accelerate product innovation, enabling our customers to continue to bring life-changing medical products and research to market faster,” said Peter O’Blenis, CEO of Evidence Partners. “As the market leader for AI-enabled literature review software, the company will further invest in go-to-market initiatives to ensure that the global research community is aware of and can access this important technology.”
“The Evidence Partners team has built an industry-leading product and a global customer base of institutions and enterprises—all without external capital,” said Andrew Pinkerton, Partner at Thomvest Ventures, a cross-stage venture capital fund backed by Peter Thomson. “We are excited to partner with Evidence Partners as they enter their next phase of growth.”
Related Articles
-
The partnership brings together Evidence Partners' literature review platform, DistillerSR, and Akra Team's strategic regulatory services.
-
The FDA is asking stakeholders to submit public comments on how it should use any portion of the user fee funding that may be distributed to external organizations—other than NEST—to support premarket RWE in medical device evaluation and development.
-
More and more, the quality of real-world evidence (RWE)—gathered from remote patient monitoring data, product and disease registry data, and patient feedback—determines whether a medical device is approved and, in some instances, for how long. Yet some medical device manufacturers…
-
Before product developers can more confidently design RWE studies and venture away from the traditional path of lengthy prospective studies, industry must overcome several challenges. This article provides insight on these barriers and perspective on how industry might fully realize…
